Raymond James Financial
RDHL

Raymond James Financial’s Redhill Biopharma RDHL Stock Holding History

Raymond James Financial’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-204
Closed -$396 – 6362
2025
Q2 		$396 Buy
+204
New +$416 ﹤0.01% 6700

Other funds holding RDHL

GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $350M AUM 21.03% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return

Raymond James Financial's RDHL Position: Q3 2025 in Review

Raymond James Financial sold out of Redhill Biopharma (RDHL) in Q3 2025, closing a stake of 204 shares — an estimated $396 sold.

Raymond James Financial first reported a position in RDHL in Q2 2025 and held it in 1 quarter. The position peaked at $396 in Q2 2025. 14 funds tracked by Wall St. Rank hold RDHL as of Q3 2025.

  • Raymond James Financial reported no remaining Redhill Biopharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 204 Redhill Biopharma shares in Q3 2025, an estimated $396.
  • Raymond James Financial first reported a position in Redhill Biopharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Redhill Biopharma position peaked at $396 in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.